Promising results from Phase III clinical trial of a peptide vaccine for advanced melanoma

Immunotherapy

Volumn 1, Issue 4, 2009, Pages 521-

  Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100[209-217]; INTERLEUKIN 2; MELANOMA VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT RESPONSE;

EID: 77953462748     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.42     Document Type: Short Survey

References (1)

1. Sources: Schwartzentruber DJ, Lawson D, Richards J et al.: A Phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. Presented at: American Society of Clinical Oncology 2009 Annual Meeting, Orlando, FL, USA, 29 May-2 June 2009; University of Texas MD Anderson Cancer Center, TX, USA: www.mdanderson.org